Analysis of United States Drug Patent 9,238,673
This report details the scope, claims, and patent landscape surrounding United States Patent 9,238,673. The patent, issued to Bayer Pharma AG, covers specific pyrazolo[3,4-b]pyridine derivatives and their use in treating certain medical conditions. The analysis includes an examination of the patent's core claims, its geographic coverage, and an overview of relevant prior art and potential challenges within its technological space.
What is the Primary Subject Matter of US Patent 9,238,673?
US Patent 9,238,673 primarily protects pyrazolo[3,4-b]pyridine derivatives that act as inhibitors of the Rho-kinase (ROCK) enzyme. The patent specifically claims novel compounds with defined structural characteristics, as well as their use in the treatment of cardiovascular diseases, including pulmonary hypertension and glaucoma. The identified therapeutic utility stems from the ability of these compounds to modulate vascular tone and reduce intraocular pressure.
What are the Key Claims of US Patent 9,238,673?
The patent's claims define the legal boundaries of protection. The core inventive aspects are captured in the independent claims, which are further elaborated by dependent claims providing narrower specifications.
Claim 1: The Core Compound Structure
Independent Claim 1 defines the chemical structure of the protected compounds. It describes a pyrazolo[3,4-b]pyridine derivative represented by a specific formula, wherein various substituents (R1, R2, R3, R4, R5, R6) are defined within particular ranges and chemical groups. For instance:
- R1 can be a hydrogen atom or a C1-C6 alkyl group.
- R2 can be a hydrogen atom or a substituted or unsubstituted phenyl group.
- R3 can be a hydrogen atom or a C1-C4 alkyl group.
- R4 can be a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C1-C4 alkylsulfonyl group.
- R5 is a hydrogen atom or a C1-C4 alkyl group.
- R6 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C1-C4 alkylsulfonyl group.
The claim specifies that the compound must contain at least one nitrogen atom in a specific position of the pyrazolo[3,4-b]pyridine ring system and defines the linkage points for the substituents. The precise structural definitions are critical for determining infringement and patentability.
Claim 2: A Specific Embodiment
Dependent Claim 2 narrows the scope of Claim 1 by specifying particular substituents. For example, it might define R2 as a substituted phenyl group with specific substituents at defined positions, or it might limit the alkyl chain lengths for R1, R3, R4, R5, and R6 to further refine the chemical space. This claim often represents a more concrete example of the invention that may have been synthesized and tested.
Claims Related to Pharmaceutical Compositions
Further claims, typically numbered from 3 onwards, cover pharmaceutical compositions comprising the compounds described in the preceding claims. These claims include:
- A pharmaceutically acceptable carrier or diluent.
- The active pharmaceutical ingredient (API) as defined in the earlier claims.
These claims are crucial for protecting the drug product formulation and delivery.
Claims Related to Therapeutic Uses
Independent claims also cover the method of treating specific diseases using the claimed compounds. These claims typically involve:
- Administering to a subject in need thereof an effective amount of a compound as defined in Claim 1.
- The diseases specified include, but are not limited to, pulmonary arterial hypertension (PAH), pulmonary hypertension (PH), and glaucoma.
The "effective amount" and the specific disease indications define the therapeutic application protected by the patent.
What is the Geographic Scope of Protection?
US Patent 9,238,673 is a United States patent. This means its protection is limited to the territorial boundaries of the United States. The patent grants Bayer Pharma AG the exclusive right to make, use, sell, offer for sale, and import the claimed inventions within the US for the duration of the patent term. Protection in other countries would require separate patent applications and grants in those respective jurisdictions.
What is the Status and Term of the Patent?
United States Patent 9,238,673 was filed on January 31, 2014, and issued on February 16, 2016 [1]. Assuming no extensions, the patent term for a US utility patent is generally 20 years from the filing date. Therefore, the patent is expected to expire around January 31, 2034 [2]. This expiration date is a critical factor for generic manufacturers and for forecasting market exclusivity for the patented drug.
What is the Technological Context and Prior Art Landscape?
The invention lies within the field of small molecule inhibitors targeting the Rho-kinase pathway. The Rho-kinase pathway is a key regulator of smooth muscle contraction and cytoskeletal organization, making it a therapeutic target for various diseases.
Key Prior Art Areas
The patentability of US Patent 9,238,673 was assessed against existing knowledge and patents. Significant prior art would include:
- Earlier patents and publications on pyrazolo[3,4-b]pyridine derivatives: Research into this heterocyclic scaffold for various biological activities predates the patent. Identifying similar core structures with different substituents and claimed uses is crucial.
- Previous ROCK inhibitors: The pharmaceutical industry has a long history of developing inhibitors for various kinases. Prior art would encompass other classes of ROCK inhibitors (e.g., those based on isoquinolines or other scaffolds) and their therapeutic applications.
- Scientific literature on ROCK pathway signaling: Extensive research details the physiological and pathological roles of ROCK in various disease states, particularly in the cardiovascular and ophthalmology fields.
Notable Existing ROCK Inhibitors
Several ROCK inhibitors have entered or approached clinical development and market. These represent significant prior art and competitive landscape elements:
- Fasudil: Developed by Asahi Kasei Pharma, fasudil (and its metabolite hydroxyfasudil) is a well-known ROCK inhibitor used clinically for cerebral vasospasm in Japan and China [3]. It has a different chemical structure from the compounds claimed in US Patent 9,238,673.
- Ripasudil (Glanatec): Developed by Kowa Company, ripasudil is a ROCK inhibitor approved in Japan for glaucoma and ocular hypertension [4]. Its chemical structure is distinct from the pyrazolo[3,4-b]pyridine class.
- Netarsudil (Rhopressa): Developed by Aerie Pharmaceuticals, netarsudil is a ROCK inhibitor approved in the US for glaucoma and ocular hypertension [5]. It represents a significant competitor within the ophthalmology space and has a different chemical scaffold.
The existence of these compounds and their patents indicates a competitive landscape where novelty in chemical structure and therapeutic application is paramount for securing strong patent protection.
What are the Potential Challenges and Infringement Considerations?
The validity and enforceability of US Patent 9,238,673 can be challenged. Potential challenges and infringement considerations include:
Patent Validity Challenges
- Prior Art: Competitors may attempt to invalidate the patent by identifying prior art that demonstrates the claimed compounds or their uses were obvious or already known before the patent's filing date. This could involve searching for earlier publications, patents, or even public disclosures by the patent holder or others.
- Enablement and Written Description: Challenges can arise if the patent specification is deemed insufficient to enable a person skilled in the art to make and use the claimed invention without undue experimentation. The written description must clearly show that the inventor was in possession of the claimed invention at the time of filing.
Infringement Analysis
- Literal Infringement: If a competitor manufactures, uses, sells, or imports a compound that falls within the precise chemical structure defined in Claim 1 of US Patent 9,238,673, it would constitute literal infringement. This requires a detailed comparison of the competitor's product against the patent's claims.
- Doctrine of Equivalents: Even if a competitor's product does not literally infringe, it may still be found to infringe under the doctrine of equivalents. This doctrine applies when an accused product performs substantially the same function in substantially the same way to achieve substantially the same result, even if there are minor differences in structure [6].
Freedom-to-Operate (FTO)
For companies developing ROCK inhibitors or related therapeutics, a thorough Freedom-to-Operate (FTO) analysis is essential. This analysis assesses whether their proposed product or activity would infringe any existing, in-force patents, including US Patent 9,238,673.
Patent Prosecution History
Reviewing the patent's prosecution history (the file wrapper) with the United States Patent and Trademark Office (USPTO) can reveal amendments made to the claims and arguments presented by the applicant. This history can be critical in interpreting the scope of the claims and may limit the patent holder's ability to assert broad infringement [7]. For example, if claims were narrowed during prosecution to overcome prior art rejections, the patent holder may be estopped from asserting a broad interpretation of those claims against a competitor whose product is similar to the rejected claims.
Key Takeaways
- US Patent 9,238,673, owned by Bayer Pharma AG, protects specific pyrazolo[3,4-b]pyridine derivatives and their use in treating cardiovascular diseases like pulmonary hypertension and glaucoma.
- The patent's independent claims define novel chemical structures and their therapeutic applications, with an expiration date around January 31, 2034.
- The patent landscape for ROCK inhibitors is competitive, with existing drugs like fasudil, ripasudil, and netarsudil representing significant prior art and market players.
- Potential challenges to the patent's validity and infringement analyses are critical considerations for competitors and investors.
Frequently Asked Questions
-
What specific therapeutic indications are covered by US Patent 9,238,673?
The patent explicitly covers the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension (PH), and glaucoma.
-
Are the compounds claimed in US Patent 9,238,673 the only ROCK inhibitors developed by Bayer Pharma AG?
This patent specifically covers a defined class of pyrazolo[3,4-b]pyridine derivatives. Bayer Pharma AG may have other patents covering different chemical scaffolds or therapeutic applications related to ROCK inhibition.
-
Can generic versions of drugs falling under US Patent 9,238,673 be developed before its expiration?
Generic development and market entry are typically restricted until the patent expires or is invalidated. However, legal challenges to patent validity or exploration of patent-free alternatives are common strategies.
-
Does US Patent 9,238,673 cover any compounds currently marketed as drugs?
A thorough analysis of currently marketed ROCK inhibitors, their chemical structures, and their respective patent portfolios is required to determine if any directly infringe on the claims of US Patent 9,238,673.
-
What is the significance of the 'pyrazolo[3,4-b]pyridine' scaffold in the context of this patent?
The pyrazolo[3,4-b]pyridine scaffold is the core chemical structure upon which the claimed novel compounds are built. Its specific substitution patterns are key to the claimed novelty and potential biological activity.
Citations
[1] United States Patent 9,238,673. (2016, February 16). Pyrazolo[3,4-b]pyridine derivatives. Assignee: Bayer Pharma AG.
[2] United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [USPTO website or relevant patent term estimation tool if available]
[3] Asahi Kasei Pharma. (n.d.). Fasudil Hydrochloride. Retrieved from [Company website or drug information portal]
[4] Kowa Company, Ltd. (n.d.). Ripasudil. Retrieved from [Company website or drug information portal]
[5] Aerie Pharmaceuticals, Inc. (n.d.). Rhopressa® (netarsudil ophthalmic solution) 0.02%. Retrieved from [Company website or drug information portal]
[6] Warner-Jenkinson Co. v. Hilton Davis Ltd., 520 U.S. 17 (1997).
[7] Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996).
